Please ensure Javascript is enabled for purposes of website accessibility

Why Vir Biotechnology Rocketed Higher Today

By Prosper Junior Bakiny – May 18, 2020 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is making progress in its efforts to develop a therapy for COVID-19.

What happened?

Shares of Vir Biotechnology (VIR 0.89%) soared on Monday after the company announced some exciting news regarding its efforts to develop a treatment for COVID-19. Specifically, promising research findings from Vir's attempts to defeat COVID-19 were published in a paper in the journal Nature, one of the world's leading science journals. Vir's stock closed the day up by 32.1%. 

So what

The paper in question, entitled "Cross-neutralization of SARS-CoV and SARS-CoV-2 by a human monoclonal antibody" (Pinto, et al., Nature), describes how an antibody called S309 was isolated from a patient who recovered from severe acute respiratory syndrome (SARS) back in 2003. According to the authors of the paper, S309 "has been shown to prevent SARS-CoV-2 live virus infection of cells." This promising antibody could remain effective even if the SARS-CoV-2 virus evolves, at least according to Vir's Chief Scientific Officer, Herbert Virgin. 

Vir is now moving forward in its quest to develop a treatment for COVID-19. The company's leading therapies for the rapidly spreading disease are called VIR-7831 and VIR-7832, and both are based on S309. Vir is collaborating with GlaxoSmithKline (GSK 0.24%) in this potentially lucrative project, and the two companies expect to start clinical testing this summer.

A person wearing gloves and holding a test tube filled with blood for coronavirus testing.

Image Source: Getty Images.

Now what

The race to find a vaccine or a treatment for COVID-19 is heating up, and investors continue to load up on shares of those companies that are at the forefront of this hunt. This explains why Vir's shares have soared by more than 200% year to date. However, there are still many roadblocks the biotech company will have to overcome before it can hope to market any treatment for COVID-19. And given that a lot can go wrong for Vir in the meantime, it might be best to watch this one from the sidelines. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$19.28 (0.89%) $0.17
GSK Stock Quote
GSK
GSK
$29.43 (0.24%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.